1. Development of an inactivated vaccine candidate for SARS-CoV-2
2. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial;Zhang;Lancet Infect Dis,2021
3. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial;Wu;Lancet Infect Dis,2021
4. Naranjo CA , Busto U , Sellers EM , et al . A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239245. doi:10.1038/clpt.1981.154
5. ACR COVID-19 Vaccine Clinical Guidance Task Force . COVID-19 vaccine clinical guidance summary for patients with rheumatic and musculoskeletal diseases, 2021. Available: https://www.rheumatology.org/Portals/0/Files/COVID-19-Vaccine-Clinical-Guidance-Rheumatic-Diseases-Summary.pdf